
Alnylam Pharmaceuticals, Inc.: shareholders and insiders
Price
$143.82
November 20, 2026Market cap $19.1B
What Ploutos Investor adds for Alnylam Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2008
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 17, 2026, from their own Form 4 filings.
Bought on the market
$543.1K
2 people
Sold on the market
$27M
8 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan40%
- The rest60%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $543.1K by 2 people·sold $27M by 8 people
- 2025: no buys, no sales
- 2026: bought $543.1K by 2 people, sold $27M by 8 people
- Nov 13, 2026Yvonne GreenstreetChief Executive OfficerKind
- Nov 10, 2026David E I PyottDirectorKind
- Nov 10, 2026Charles Elliott SigalDirectorKind
- Nov 9, 2026Amy W SchulmanDirectorKind
- Oct 2, 2026Bryan SupranEVP, CLO and SecretaryKind
- Sep 19, 2026Yvonne GreenstreetChief Executive OfficerKind
- Jun 1, 2026David E I PyottDirectorKind10b5-1
- Jun 1, 2026David E I PyottDirectorKind10b5-1
- Jun 1, 2026David E I PyottDirectorKind10b5-1
- Jun 1, 2026David E I PyottDirectorKind10b5-1
- Jun 1, 2026David E I PyottDirectorKind10b5-1
- Jun 1, 2026David E I PyottDirectorKind10b5-1
- Apr 6, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 6, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 6, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 6, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 6, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
- Apr 2, 2026Melissa McLaughlinChief Human Resources OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Yvonne GreenstreetChief Executive Officer | 11.0K | – | – | Form 4 | |
| Nov 10, 2026 | David E I PyottDirector | 3,780 | $71.99 | $272.1K | Form 4 | |
| Nov 10, 2026 | Charles Elliott SigalDirector | 1,600 | $152.25 | $243.6K | Form 4 | |
| Nov 9, 2026 | Amy W SchulmanDirector | 1,910 | $156.82 | $299.5K | Form 4 | |
| Oct 2, 2026 | Bryan SupranEVP, CLO and Secretary | 1,758 | $226.88 | $398.9K | Form 4 | |
| Sep 19, 2026 | Yvonne GreenstreetChief Executive Officer | 107 | – | – | Form 4 | |
| Jun 1, 2026 | David E I PyottDirector | 10b5-1 | 3,830 | – | – | Form 4 |
| Jun 1, 2026 | David E I PyottDirector | 10b5-1 | 921 | $297.71 | $274.2K | Form 4 |
| Jun 1, 2026 | David E I PyottDirector | 10b5-1 | 1,175 | $298.91 | $351.2K | Form 4 |
| Jun 1, 2026 | David E I PyottDirector | 10b5-1 | 1,222 | $299.87 | $366.4K | Form 4 |
| Jun 1, 2026 | David E I PyottDirector | 10b5-1 | 495 | $300.72 | $148.9K | Form 4 |
| Jun 1, 2026 | David E I PyottDirector | 10b5-1 | 17 | $302.65 | $5.1K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 56 | $320.14 | $17.9K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 909 | $329.76 | $299.8K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 829 | $330.46 | $274.0K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 293 | $331.89 | $97.2K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 199 | $333.94 | $66.5K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 147 | $320.62 | $47.1K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 245 | $322.86 | $79.1K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 224 | $321.64 | $72.0K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 86 | $319.69 | $27.5K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 81 | $323.64 | $26.2K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 8 | $325.49 | $2.6K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 359 | $317.44 | $114.0K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlinChief Human Resources Officer | 10b5-1 | 265 | $316.61 | $83.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ALNY's officers and directors from 2006 up to November 20, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class9.50%
- Capital World InvestorsShare of class8.20%
- Capital Research Global InvestorsShare of class7.10%
- Vanguard Capital ManagementShare of class5.35%
- Vanguard Portfolio ManagementShare of class5.03%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 9.50% | 12.68M | Nov 5, 20263 filings since Nov 5, 2025 | 13G/A | |
| Capital World Investors | 8.20% | 10.92M | May 14, 2026 | 13G/A | |
| Capital Research Global Investors | 7.10% | 9.47M | May 14, 20262 filings since Feb 13, 2025 | 13G/A | |
| Vanguard Capital Management | 5.35% | 7.10M | Apr 29, 2026 | 13G | |
| Vanguard Portfolio Management | 5.03% | 6.73M | Oct 30, 2026 | 13G |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 26, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter-2.0%
- AQR CapitalIn the quarter+133%
- Millennium Mgmt (Englander)In the quarter+20%
- Bridgewater (Dalio)In the quarter-71%
- Citadel Advisors (Griffin)In the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 1.08M | -2.0% | $267M | 0.17% |
| AQR Capital | 1.70M | +133% | $419M | 0.12% |
| Millennium Mgmt (Englander) | 377.7K | +20% | $93M | 0.07% |
| Bridgewater (Dalio) | 28.5K | -71% | $7.0M | 0.03% |
| Citadel Advisors (Griffin) | – | – | 0.03% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 4.95% of its shares outstanding were held short, -14.8% since the report before.
- Shares held short
- 6.57M
- 4.95%
- Since the report before7.71M on Sep 30, 2026
- -14.8%
- 5.1
- 1.29M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 62%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 5.27M
- Nov 15, 2023: Shares held short 5.19M
- Nov 30, 2023: Shares held short 5.09M
- Dec 15, 2023: Shares held short 4.99M
- Dec 29, 2023: Shares held short 4.73M
- Jan 12, 2024: Shares held short 4.33M
- Jan 31, 2024: Shares held short 4.01M
- Feb 15, 2024: Shares held short 3.99M
- Feb 29, 2024: Shares held short 3.04M
- Mar 15, 2024: Shares held short 2.69M
- Mar 28, 2024: Shares held short 2.80M
- Apr 15, 2024: Shares held short 2.50M
- Apr 30, 2024: Shares held short 2.63M
- May 15, 2024: Shares held short 2.54M
- May 31, 2024: Shares held short 2.48M
- Jun 14, 2024: Shares held short 2.13M
- Jun 28, 2024: Shares held short 3.68M
- Jul 15, 2024: Shares held short 4.49M
- Jul 31, 2024: Shares held short 4.33M
- Aug 15, 2024: Shares held short 4.52M
- Aug 30, 2024: Shares held short 3.77M
- Sep 13, 2024: Shares held short 4.45M
- Sep 30, 2024: Shares held short 4.51M
- Oct 15, 2024: Shares held short 4.84M
- Oct 31, 2024: Shares held short 3.70M
- Nov 15, 2024: Shares held short 3.74M
- Nov 29, 2024: Shares held short 3.39M
- Dec 13, 2024: Shares held short 3.49M
- Dec 31, 2024: Shares held short 3.35M
- Jan 15, 2025: Shares held short 3.15M
- Jan 31, 2025: Shares held short 2.94M
- Feb 14, 2025: Shares held short 3.22M
- Feb 28, 2025: Shares held short 2.49M
- Mar 14, 2025: Shares held short 2.54M
- Mar 31, 2025: Shares held short 2.99M
- Apr 15, 2025: Shares held short 3.06M
- Apr 30, 2025: Shares held short 3.15M
- May 15, 2025: Shares held short 3.68M
- May 30, 2025: Shares held short 3.45M
- Jun 13, 2025: Shares held short 3.38M
- Jun 30, 2025: Shares held short 3.33M
- Jul 15, 2025: Shares held short 3.38M
- Jul 31, 2025: Shares held short 3.24M
- Aug 15, 2025: Shares held short 3.43M
- Aug 29, 2025: Shares held short 3.97M
- Sep 15, 2025: Shares held short 3.72M
- Sep 30, 2025: Shares held short 3.51M
- Oct 15, 2025: Shares held short 3.99M
- Oct 31, 2025: Shares held short 3.77M
- Nov 14, 2025: Shares held short 4.28M
- Nov 28, 2025: Shares held short 3.96M
- Dec 15, 2025: Shares held short 4.18M
- Dec 31, 2025: Shares held short 5.53M
- Jan 15, 2026: Shares held short 5.57M
- Jan 30, 2026: Shares held short 5.28M
- Feb 13, 2026: Shares held short 5.24M
- Feb 27, 2026: Shares held short 4.57M
- Mar 13, 2026: Shares held short 4.37M
- Mar 31, 2026: Shares held short 5.06M
- Apr 15, 2026: Shares held short 5.03M
- Apr 30, 2026: Shares held short 4.77M
- May 15, 2026: Shares held short 5.40M
- May 29, 2026: Shares held short 5.30M
- Jun 15, 2026: Shares held short 5.44M
- Jun 30, 2026: Shares held short 5.80M
- Jul 15, 2026: Shares held short 5.77M
- Jul 31, 2026: Shares held short 4.80M
- Aug 14, 2026: Shares held short 4.77M
- Aug 31, 2026: Shares held short 6.34M
- Sep 15, 2026: Shares held short 7.19M
- Sep 30, 2026: Shares held short 7.71M
- Oct 15, 2026: Shares held short 6.57M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading26.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 26.2% of the shares in the reported trades were short sales, against 23.7% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 26.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 23.7%
- Change
- +2.5 pts
- Short sales a dayon average, of 1.23M shares
- 322.4K
- More than atof 3,674 US-listed companies, same days
- 3%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 25.8%
- Oct 15, 2026: Short sales 30%
- Oct 16, 2026: Short sales 40.5%
- Oct 19, 2026: Short sales 32.6%
- Oct 20, 2026: Short sales 46.2%
- Oct 21, 2026: Short sales 49.3%
- Oct 22, 2026: Short sales 31.8%
- Oct 23, 2026: Short sales 45.6%
- Oct 26, 2026: Short sales 28.7%
- Oct 27, 2026: Short sales 44.2%
- Oct 28, 2026: Short sales 34.8%
- Oct 29, 2026: Short sales 18.1%
- Oct 30, 2026: Short sales 8.6%
- Nov 2, 2026: Short sales 16%
- Nov 3, 2026: Short sales 18.2%
- Nov 4, 2026: Short sales 25.2%
- Nov 5, 2026: Short sales 31.2%
- Nov 6, 2026: Short sales 19.2%
- Nov 9, 2026: Short sales 32.9%
- Nov 10, 2026: Short sales 25.8%
- Nov 11, 2026: Short sales 9.5%
- Nov 12, 2026: Short sales 31.3%
- Nov 13, 2026: Short sales 23.1%
- Nov 16, 2026: Short sales 38.1%
- Nov 17, 2026: Short sales 27.7%
- Nov 18, 2026: Short sales 33.6%
- Nov 19, 2026: Short sales 28.9%
- Nov 20, 2026: Short sales 35.9%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Yvonne GreenstreetChief Executive OfficerDirectly85.2K
- Jeffrey V. PoultonEVP, Chief Financial OfficerDirectly63.1K
- Tolga TangulerEVP, Chief Commercial OfficerDirectly34.3K
- David E I PyottDirectorDirectly33.3K
- Amy W SchulmanDirectorDirectly26.0K
- Kevin Joseph FitzgeraldCSO & EVP, Head of ResearchDirectly20.6K
- Pushkal GargEVP Chief R&DDirectly20.4K
- Michael W BonneyDirectorDirectly16.8K
- Bryan SupranEVP, CLO and SecretaryDirectly12.8K
- Melissa McLaughlinChief Human Resources OfficerDirectly11.7K
- Colleen F ReitanDirectorDirectly5,791
- Charles Elliott SigalDirectorDirectly5,046
- Indrani Lall FranchiniEVP, CLO & SecretaryDirectly4,143
- Dennis A AusielloDirectorDirectly1,552
- Phillip A SharpDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Yvonne GreenstreetChief Executive Officer | 85.2K | – | Nov 13, 2026 | Form 4 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | 63.1K | – | Mar 4, 2026 | Form 4 |
| Tolga TangulerEVP, Chief Commercial Officer | 34.3K | – | Mar 4, 2026 | Form 4 |
| David E I PyottDirector | 33.3K | – | Nov 10, 2026 | Form 4 |
| Amy W SchulmanDirector | 26.0K | – | Nov 9, 2026 | Form 4 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | 20.6K | – | Mar 5, 2026 | Form 4 |
| Pushkal GargEVP Chief R&D | 20.4K | – | Mar 5, 2026 | Form 4 |
| Michael W BonneyDirector | 16.8K | – | Aug 18, 2025 | Form 4 |
| Bryan SupranEVP, CLO and Secretary | 12.8K | – | Oct 2, 2026 | Form 4 |
| Melissa McLaughlinChief Human Resources Officer | 11.7K | – | Apr 6, 2026 | Form 4 |
| Colleen F ReitanDirector | 5,791 | – | Sep 9, 2025 | Form 4 |
| Charles Elliott SigalDirector | 5,046 | – | Nov 10, 2026 | Form 4 |
| Indrani Lall FranchiniEVP, CLO & Secretary | 4,143 | – | Feb 28, 2024 | Form 4 |
| Dennis A AusielloDirector | 1,552 | – | Aug 14, 2025 | Form 4 |
| Phillip A SharpDirector | – | – | Jan 23, 2025 | Form 4 |
A lower bound: it counts only the 15 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund3.12%
- IWPiShares Russell Mid-Cap Growth ETFWeight in the fund1.10%
- TCAFT. Rowe Price Capital Appreciation Equity ETFWeight in the fund1.01%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.96%
- VOTVanguard Mid-Cap Growth Index FundWeight in the fund0.88%
- CGGRCapital Group Growth ETFWeight in the fund0.71%
- FMDEFidelity Enhanced Mid Cap Core ETFWeight in the fund0.52%
- CGBLCapital Group Core Balanced ETFWeight in the fund0.51%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.48%
- VXFVanguard Extended Market Index FundWeight in the fund0.47%
49 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 825
- Q4 2025: Managers 853
- Q1 2026: Managers 798
- Q2 2026: Managers 790
Institutional investors by quarter
The fund managers holding ALNY, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 790 managers held 134M shares, worth $40.2B. During the quarter 86 opened a position, 94 closed one, 319 added and 277 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+3.1%
- Capital World InvestorsIn the quarter+3.2%
- BlackRockIn the quarter+4.4%
- Capital Research Global InvestorsIn the quarter+3.0%
- Vanguard Portfolio ManagementIn the quarter+0.7%
- Vanguard Capital ManagementIn the quarter+1.4%
- T. Rowe Price Investment ManagementIn the quarter+8.6%
- InvescoIn the quarter-7.9%
- State StreetIn the quarter+7.0%
- JPMorgan ChaseIn the quarter-58%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 15.02M | +3.1% | $4.5B |
| Capital World Investors | 11.14M | +3.2% | $3.4B |
| BlackRock | 10.91M | +4.4% | $3.3B |
| Capital Research Global Investors | 9.75M | +3.0% | $2.9B |
| Vanguard Portfolio Management | 6.54M | +0.7% | $2.0B |
| Vanguard Capital Management | 6.03M | +1.4% | $1.8B |
| T. Rowe Price Investment Management | 5.64M | +8.6% | $1.7B |
| Invesco | 3.75M | -7.9% | $1.1B |
| State Street | 3.56M | +7.0% | $1.1B |
| JPMorgan Chase | 2.68M | -58% | $785M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Alnylam Pharmaceuticals's filings show?
Who buys and sells is one part of Alnylam Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ALNY's insiders bought or sold?
From Jun 3, 2026 to Nov 17, 2026 Alnylam Pharmaceuticals's insiders bought $543.1K and sold $1.5M of shares on the market. 74% of the sales were under set 10b5-1 plans.
Which well-known managers hold ALNY?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $419M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.